Metabolic syndrome and prostate cancer: a review.

Nobes, J P; Langley, S E M; Laing, R W

Nobes, J P; Langley, S E M; Laing, R W.

Afiliación

Nobes JP; St. Luke's Cancer Centre, The Royal Surrey County Hospital, Guildford, Surrey, UK. jpnobes@gmail.com

Clin Oncol (R Coll Radiol) ; 21(3): 183-91, 2009 Apr.

Article en En | MEDLINE | ID: mdl-19111451

RESUMEN

Androgen deprivation therapy is widely used in a number of different settings in the treatment of prostate cancer. This overview will look at the current evidence for the potential development of metabolic syndrome and cardiovascular disease as a consequence of this therapy, and highlight strategies aimed at their prevention. The relationship between metabolic syndrome and prostate cancer development will also be examined.

Asunto(s)

Síndrome Metabólico/etiología; Neoplasias de la Próstata/terapia; Antagonistas de Andrógenos/efectos adversos; Antagonistas de Andrógenos/uso terapéutico; Hormona Liberadora de Gonadotropina/agonistas; Humanos; Masculino; Orquiectomía/efectos adversos; Neoplasias de la Próstata/metabolismo

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Síndrome Metabólico Límite: Humans / Male Idioma: En Revista: Clin Oncol (R Coll Radiol) Asunto de la revista: NEOPLASIAS Año: 2009 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google